Ferrara标准预测AML强化化疗早期死亡准确性的验证研究
该研究基于655例接受强化化疗的成人AML或高危髓系肿瘤患者,评估Ferrara不适宜标准预测早期死亡和生存的准确性。30%患者符合至少一条不适宜标准,其总生存显著缩短(中位4.8个月 vs 36.8个月,P<.001)。Ferrara标准预测第28天和第100天死亡率的AUC分别为0.76和0.79,加入体能状态和白蛋白后AUC可达0.84-0.85。
要点
- 30%接受强化化疗的AML患者符合Ferrara不适宜标准,中位总生存仅4.8个月。
- Ferrara标准预测第28天和第100天死亡率的AUC为0.76和0.79,优于既往治疗相关死亡率评分。
- 加入体能状态和白蛋白可显著提高预测准确性,AUC最高达0.85。
核心结论
- Ferrara不适宜标准是预测AML强化化疗后短期死亡率良好的工具,其数据可作为F-fit和F-unfit患者强化化疗预期结局的基准。
研究设计与样本
- 回顾性评估655例接受 curative-intent 诱导或再诱导化疗的成人AML或高危髓系肿瘤患者,化疗方案包括7+3、CLAG-M或减量CLAG-M。
- 基于Ferrara标准评估患者是否不适宜(F-unfit),并分析该评估对早期死亡和生存预测的准确性。
主要发现
- 197例(30%)患者符合至少一条Ferrara不适宜标准(F-unfit)。
- F-unfit患者总生存显著短于F-fit患者(中位4.8个月,95%CI 3.6-6.5个月 vs 36.8个月,95%CI 27.4-73.0个月,P<.001)。
- Ferrara标准单独预测第28天和第100天死亡率的AUC分别为0.76和0.79,优于既往治疗相关死亡率评分(AUC 0.66和0.62)。
- 加入体能状态和白蛋白等协变量后,预测第28天或第100天死亡率的AUC可提高至0.84-0.85。
- 多变量模型预测总生存的c-statistic最高为0.75。
关键数值与推荐
- Ferrara不适宜标准:由意大利专家小组提出的概念性标准,用于判断患者是否适合强化化疗。
- 研究中使用既往治疗相关死亡率评分作为对照,二分类切点为≤13.1 vs >13.1。
临床怎么用
- 临床可用Ferrara标准识别不适合强化化疗的AML患者,辅助治疗决策。
- 结合体能状态和白蛋白可进一步提高早期死亡预测准确性。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an Italian panel of experts are widely used for this purpose. How accurately these Ferrara criteria predict fitness for intensive chemotherapy is unknown. PATIENTS AND METHODS: We assessed the fitness of adults undergoing intensive AML therapy based on Ferrara criteria and determined the accuracy of this assessment for early mortality and survival prediction. RESULTS: Among 655 adults who received curative-intent induction or reinduction chemotherapy with 7 days of standard-dose cytarabine and 3 days of an anthracycline ("7+3") CLAG-M (cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone), or reduced-dose CLAG-M, 197 (30%) met at least one of the criteria defining unfitness for intensive chemotherapy (F-unfit). Compared with F-fit patients, the overall survival of F-unfit patients was significantly shorter (median, 4.8 months; 95% CI, 3.6 to 6.5 months v 36.8 months; 95% CI, 27.4 to 73.0 months; P < .001). When used alone, the Ferrara unfitness assessment was more accurate in predicting day 28 and day 100 mortality than the treatment-related mortality score we developed previously (used binary, ≤ 13.1 v > 13.1), as indicated by area under the receiver operating characteristic curve (AUC) values of 0.76 and 0.79 versus 0.66 and 0.62. The predictive accuracy of the Ferrara unfitness assessment could be significantly improved by including additional covariates such as performance status and albumin, yielding AUCs as high as 0.84-0.85 for the prediction of day 28 or day 100 mortality. Prediction of overall survival was less accurate, yielding a c-statistic value as high as 0.75 in multivariable models. CONCLUSION: Ferrara unfitness criteria provide a good prediction tool for shorter-term mortality after intensive AML chemotherapy. Our data may serve as a benchmark for expected outcomes with intensive chemotherapy in F-fit and F-unfit patients.
引用
- Palmieri R, Othus M, Halpern AB, et al. Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. J Clin Oncol. 2020. PMID: 33030979. doi:10.1200/JCO.20.01392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。